The global Liver Cancer Diagnostics Market is valued at USD 11.5 Billion in 2024 and is projected to reach a value of USD ...

Illumina's divestiture of GRAIL boosts financials, while strong gross margins and DNA sequencing growth drive potential. See ...

Illumina (NASDAQ:ILMN) stock dips as Scotiabank downgrades. However, peers Danaher (DHR) stock and Thermo Fisher (TMO) stock win upgrades. Read more here.

Shares of Illumina Inc. (NASDAQ:ILMN) dropped 3.8% on Wednesday after Citi downgraded the stock from Neutral to Sell, warning ...

Illumina’s first quarter results reflected ongoing challenges in the global genomics market, as the company’s performance ...

According to a comprehensive market research report titled "Neurogenomics Market Size, Share, Forecast, & Trends Analysis by Offering ...

Explore the future of proteomics where new biomarkers are redefining disease, possibly outpacing genomics. With venture capital backing and double-digit growth, the market forecasts suggest ...

Macroeconomic developments and geopolitical issues, especially concerning China, have led to adjustments in full-year 2025 projections. Despite these headwinds, some analysts believe that Illumina’s ...

Despite these headwinds, some analysts believe that Illumina’s financials are relatively de-risked compared to its peers, with long-term targets remaining intact when excluding China.

Illumina Inc. cut its full-year adjusted profit guidance for the second time in three months as it grapples with the impact of tariffs and China banning imports of its gene-sequencing machines.